VanEck Associates’s Pacira BioSciences PCRX Stock Holding History

VanEck Associates’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-451	Closed	-$15K	–	904
2016 Q4	$15K	Buy	451 +223	+98%	+$7.44K	﹤0.01%	874
2016 Q3	$8K	Sell	228 -119	-34%	-$4.66K	﹤0.01%	864
2016 Q2	$12K	Buy	347 +33	+11%	+$1.62K	﹤0.01%	841
2016 Q1	$17K	Buy	+314	New	+$18.4K	﹤0.01%	807

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VanEck Associates's PCRX Position: Q1 2017 in Review

VanEck Associates sold out of Pacira BioSciences (PCRX) in Q1 2017, closing a stake of 451 shares — an estimated $15K sold.

VanEck Associates first reported a position in PCRX in Q1 2016 and held it in 4 quarters. The position peaked at $17K in Q1 2016. 192 funds tracked by Wall St. Rank hold PCRX as of Q1 2017.

VanEck Associates reported no remaining Pacira BioSciences position as of Q1 2017 after selling out during the quarter.
VanEck Associates sold 451 Pacira BioSciences shares in Q1 2017, an estimated $15K.
VanEck Associates first reported a position in Pacira BioSciences in Q1 2016 and held it in 4 quarters.
VanEck Associates's Pacira BioSciences position peaked at $17K in Q1 2016.
192 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2017.

Based on VanEck Associates's 13F filing for Q1 2017, filed 11 May 2017.